| Name | Cycloleucine |
| Description | Cycloleucine is an antagonist of NMDA receptor associated glycine receptor with a Ki of 600 μM. Cycloleucine is also a competitive inhibitor of S-adenosyl-methionine mediated methylation with anxiolytic and cytostatic effects. |
| In vitro | Cytostatic (10 µg/mL) inhibits the viability of human KB and mouse L1210s leukemia cell lines. Cycloleucine (4-40 mM; 3 h) blocks internal methylation of viral RNA in B77 transformed chick embryo fibroblasts. Cycloleucine (40 mM; 24 h) blocks the formation of both m6A and the penultimate Gm in B77 38S RNA subunits by greater than 90%[2]. |
| In vivo | Cycloleucine (0.5, 1.0, 2.0, 4 µg/µL; intracerebroventrically) increases time spent in open arms, open arm entries, and extreme arrivals in rats[3]. In Semliki Forest virus strain A7(74) infected and control mice, Cycloleucine reduces thymus and spleen weights[4]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 45 mg/mL (348.41 mM), Sonication is recommended.
DMSO : < 1 mg/mL (insoluble or slightly soluble), Sonication is recommended.
|
| Keywords | Cycloleucine | inhibit | NMDA | cytostatic | Inhibitor | methylations | ATP | nucleic | Ionotropic glutamate receptors | anxiolytic | transferase | iGluR | glycine |
| Inhibitors Related | Halothane | Riluzole | O-Phospho-L-serine |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Neurotransmitter Receptor Compound Library | Inhibitor Library | Neuroprotective Compound Library | Bioactive Compounds Library Max |
United States
